[Eli Lilly and Company](https://www.lillyinvestigatorresearch.com)

February 15, 2026 (Lebrikizumab RFPs, US) | June 15, 2026 (Mirkizumab RFP, Canada)

Support may include study drug and/or financial support; funding levels are determined per proposal and RFP.

Supports investigator-initiated clinical research aligned with Lilly's therapeutic interests via competitive RFPs.

Proposals must address specific RFP topics and be fully managed by the applicant's institution.

--- ## Description The Competitive Clinical Research Grant from Eli Lilly and Company provides support for external, investigator-initiated research projects in key therapeutic areas. Funding is offered through a competitive Request for Proposal (RFP) process, where Lilly posts specific research topics and deadlines. Selected projects may receive study drug and/or financial support, but all aspects of study design, conduct, and regulatory sponsorship are the responsibility of the grantee. Proposals are reviewed by global committees of Lilly medical and scientific staff, with possible input from external experts. --- ## Due Dates - February 15, 2026: Full application deadline for RFP: Efficacy of Lebrikizumab in patients with fibrosing skin conditions (US) - February 15, 2026: Full application deadline for RFP: How does lebrikizumab impact post-inflammatory dyspigmentation in patients with moderate to severe atopic dermatitis (US) - June 15, 2026: Full application deadline for RFP in Canada: Real-world effectiveness of mirkizumab in IBD and disease-state epidemiology in overweight and/or obese individuals living with IBD in Canada --- ## Funding Amount - Support may include provision of Lilly study drug and/or financial support. - Funding levels are determined based on the scope and requirements of each proposal and as specified in the respective RFPs. - No explicit maximum or minimum award amount is published; consult the RFP PDF for any topic-specific budget guidance. --- ## Eligibility - Open to independent, external investigators and research institutions. - Applicants must be able to design, sponsor, and conduct clinical research in the relevant country (e.g., Canada for the mirkizumab RFP). - Proposals must directly address the focus area(s) specified in the posted RFP. - The grantee holds full responsibility for study design, regulatory compliance, and conduct. --- ## Application Process - Review the specific RFP(s) of interest on the [Lilly Investigator Research Competitive Grants page](https://www.lillyinvestigatorresearch.com/competitive-grants#request-for-proposals-efficacy-of-lebrikizumab-in-patients-with-fibrosing-skin-c). - Download the proposal form provided for each RFP. - Complete the form in accordance with the RFP instructions. - Submit the completed proposal via email to the address specified in the RFP (typically CCRG@lilly.com). - Proposals are reviewed by Lilly’s global committees, with possible external expert input. - Approved projects are managed and sponsored by the applicant’s institution. --- ## Additional Information - Each RFP details the scientific focus, eligibility, and submission requirements. - Late submissions are generally not accepted. - Applicants are encouraged to contact the program for clarifications or with questions regarding eligibility or proposal content. --- ## External Links - [Eli Lilly Competitive Clinical Research Grant Program Overview](https://www.lillyinvestigatorresearch.com/competitive-grants#request-for-proposals-efficacy-of-lebrikizumab-in-patients-with-fibrosing-skin-c) - [Main Lilly Investigator Research Portal](https://www.lillyinvestigatorresearch.com) - [Contact Page for Investigator Research](https://www.lillyinvestigatorresearch.com/contact-us) - [FAQs](https://www.lillyinvestigatorresearch.com/FAQs) --- ## Contact Information | Contact Type | Details | |--------------|---------| | General Inquiries | [Contact Form](https://www.lillyinvestigatorresearch.com/contact-us) | | Proposal Submission | CCRG@lilly.com (as specified in RFPs) | ---

Competitive Clinical Research Grant

Sign in to see full grant listing